contentSlug

type

ContentSlug_ContentQuery

slug

ContentPageContentQuery

content

trendingContent

query ContentSlug_ContentQuery(
  $contentSlug: String!
  $type: [ContentType!]
) {
  ...ContentPageContentQuery_13QmVO
}

fragment CompanyDetails_Content on Content {
  __isContent: __typename
  companies {
    name
    description
    pageUrl
    id
  }
}

fragment CompanyTagList on Company {
  pageUrl
  name
  viewerIsFollowing
}

fragment ContentBasicInfo on Content {
  __isContent: __typename
  id
  type
  title
  lang
  companies {
    ...CompanyTagList
    id
  }
  ...PublishingDetails
  ...Reactions
}

fragment ContentMetadata on Content {
  __isContent: __typename
  type
  title
  lang
  pageUrl
  alternatePageUrls {
    pageUrl
    lang
  }
  imgUrl
  description
  ... on Video {
    liveTime
    videoUrl
  }
  ... on Webcast {
    liveTime
    videoUrl
  }
}

fragment ContentPageContentQuery_13QmVO on Query {
  content(slug: $contentSlug, type: $type) {
    __typename
    id
    type
    title
    isPremium
    lang
    htmlBody
    companies {
      forum {
        latestPosts {
          ...ForumPosts
        }
      }
      defaultInstrument {
        isin
        id
      }
      id
    }
    slug
    ... on CompanyReport {
      reportUrl
    }
    ... on ThirdPartyCompanyReport {
      reportUrl
    }
    ... on StockExchangeRelease {
      reportUrl
    }
    ...ContentBasicInfo
    ...ContentMetadata
    ...PriceAndRecommendation_Content
    ...CompanyDetails_Content
    ...ReportLink_Content
    ...KeyFigures_Content
  }
  ...TrendingContent_1jQ2Cn
}

fragment ForumPosts on ForumPost {
  text
  likesCount
  url
  author
  postedAt
  authorImgUrl
}

fragment KeyFigures_Content on Content {
  __isContent: __typename
  companies {
    defaultInstrument {
      estimateData {
        modelType
        reportingCurrency
      }
      snapshot {
        transaction {
          date
          actualized {
            year
            quarter
            revenue
            revenueGrowth
            ebitAdjusted
            ebitReported
            ebitda
            enterpriseValue
            epsAdjusted
            dividend
            dividendYield
            sharePrice
          }
          estimates {
            year
            quarter
            revenue
            revenueGrowth
            ebitAdjusted
            ebitReported
            ebitda
            enterpriseValue
            epsAdjusted
            dividend
            dividendYield
            sharePrice
          }
        }
      }
      id
    }
    id
  }
}

fragment PriceAndRecommendation_Content on Content {
  __isContent: __typename
  createdAt
  companies {
    id
    name
    viewerIsFollowing
    defaultInstrument {
      snapshot {
        priceData {
          date
          lastPrice
          tradeCurrency
        }
        transaction {
          date
          recommendation
          targetPrice
        }
        prevTransaction {
          recommendation
        }
      }
      id
    }
  }
}

fragment PublishingDetails on Content {
  __isContent: __typename
  createdAt
  publishers {
    name
    imgUrl
  }
  authors {
    __typename
    id
    name
    slug
    imgUrl
    jobTitle
  }
  ... on Video {
    liveTime
  }
  ... on Webcast {
    liveTime
  }
}

fragment Reactions on Content {
  __isContent: __typename
  id
  reactionGroups {
    reactionType
    reactionsCount
    viewerReacted
  }
}

fragment ReportLink_Content on Content {
  __isContent: __typename
  type
  isPremium
  ... on CompanyReport {
    reportUrl
  }
  ... on ThirdPartyCompanyReport {
    reportUrl
  }
  ... on StockExchangeRelease {
    reportUrl
  }
}

fragment TrendingContent_1jQ2Cn on Query {
  trendingContent(type: ARTICLE) {
    __typename
    id
    title
    lang
    pageUrl
    createdAt
    type
    imgUrl
    companies {
      squareLogoUrl
      id
    }
    authors {
      __typename
      imgUrl
      id
    }
    publishers {
      imgUrl
    }
  }
}


biovica-signs-agreement-with-american-health-giant

__typename

title

isPremium

lang

htmlBody

companies

createdAt

publishers

authors

reactionGroups

pageUrl

alternatePageUrls

imgUrl

description

Biovica International är ett läkemedelsbolag som inriktar sin forskning mot cancerbehandling. Bolaget utvecklar metoder för mätning utav cellproliferation, där testet tas via blodprov. Proven analyserar risken för utvecklingen av enzymet tymidinkinas, en enzym som har koppling till tumörers tillväxt. Huvudfokus återfinns inom behandling av bröstcancer. Bolaget grundades 2008 och har sitt huvudkontor i Uppsala.

Biovica International

Biovica, active in blood-based cancer monitoring, today announces that the company has entered into a commercial agreement (client bill) with one of the largest health insurance companies in...

<div class="mfn-preamble"><p><strong>Biovica, active in blood-based cancer monitoring, today announces that the company has entered into a commercial agreement (client bill) with one of the largest health insurance companies in the US, with revenues exceeding 100 billion USD. The company is both a health insurance and a health care service provider serving over 10 million Americans through its insurance policies.</strong></p></div><div class="mfn-body"><p>"This is a major breakthrough for Biovica made by our US team. The organization has been using DiviTum TKa and sees benefits for the patients as well as health economic benefits with the test, which paved the way for this agreement. If continued usage is as successful, DiviTum TKa is expected to become standard of care across this major organization. Partnerships like this are pivotal in driving sustainable revenue growth and achieving Biovica’s goal of becoming cash-flow positive and to offer DiviTum TKa to cancer patients across the world," said Anders Rylander, CEO of Biovica.</p></div><div class="mfn-footer mfn-50cffce9eda7"><p><strong class="mfn-heading-1">Contact</strong></p><hr><p>Anders Rylander, CEO<br>Phone: +46 76 666 16 47<br>E-mail:&nbsp;<a rel="noopener" href="mailto:anders.rylander@biovica.com">anders.rylander@biovica.com</a></p><p>Anders Morén, CFO<br>Phone: +46 73&nbsp;125 92 46<br>E-mail: <a rel="noopener" href="mailto:anders.moren@biovica.com">anders.moren@biovica.com</a></p></div><div class="mfn-footer mfn-about mfn-3dbc25e51d95"><p><strong class="mfn-heading-1">Biovica – Treatment decisions with greater confidence</strong></p><hr><p>Biovica develops and commercializes blood-based biomarker assays that help oncologists monitor cancer progression. Biovica’s assay, DiviTum® TKa, measures cell proliferation by detecting the TKa biomarker in the bloodstream. The assay has demonstrated its ability to provide insight to therapy effectiveness in several clinical trials. The first application for the DiviTum® TKa test is treatment monitoring of patients with metastatic breast cancer. Biovica's vision is: “Improved care for cancer patients.” Biovica collaborates with world-leading cancer institutes and pharmaceutical companies. DiviTum® TKa has received FDA 510(k) clearance in the US and is CE-marked in the EU. Biovica's shares are traded on the Nasdaq First North Premier Growth Market (BIOVIC B). FNCA Sweden AB is the company's Certified Adviser. For more information, please visit: <a rel="noopener" href="http://www.biovica.com">www.biovica.com</a></p></div><div class="mfn-footer mfn-attachment mfn-attachment-general"><p><strong class="mfn-heading-1">Attachments</strong></p><hr><p><a rel="noopener" href="https://storage.mfn.se/26fa5f14-96b8-478a-8ac9-07573d332b71/biovica-signs-agreement-with-american-health-giant.pdf" class="mfn-generated mfn-primary">Biovica signs agreement with American health giant</a></p></div>

Beställ vårt nyhetsbrev — inget användarkonto krävs!